title: Aliskiren for hypertension in adults.
abstract: High blood pressure is a major risk factor for cardiovascular disease worldwide. Drug treatments include those that target the renin-angiotensin system, a key hormone cascade in the regulation of blood pressure. One of these is aliskiren (Rasilez - Novartis), which belongs to a new class of drugs, direct renin inhibitors. Here we assess its place in managing adults with hypertension.
mesh_terms: D000328:Adult; D000577:Amides / Q000627:therapeutic use*; D017311:Amlodipine / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005650:Fumarates / Q000627:therapeutic use*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D016896:Treatment Outcome; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D017311:Amlodipine; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004338:Drug Combinations; D005650:Fumarates; D006852:Hydrochlorothiazide; D000092502:Renin Inhibitors; C446481:aliskiren